Interestingly, combined with the results of other studies that have linked variation at LPL as being associated with lower lipid levels and risk of CAD, our analysis suggests that targeting the LPL pathway may prevent NAFLD as well as other diseases such as hyperlipidemia and CAD without increasing the risk of other human diseases. This evidence concerns the gene LPL and metabolic dysfunction-associated steatotic liver disease.